{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:03Z","timestamp":1788675423752,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,14]]},"DOI":"10.7759\/cureus.79019","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:17:26Z","timestamp":1739578646000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful 30-Day Nirmatrelvir\/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma"],"prefix":"10.7759","author":[{"given":"Kou","family":"Kimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kawasuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Koshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Nabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitomo","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf S","year":"2022","unstructured":"DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MR, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022, 55:1779-98. 10.1016\/j.immuni.2022.09.006","journal-title":"Immunity"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26626","article-title":"Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report","volume":"97","author":"Blennow O","year":"2022","unstructured":"Blennow O, Salmanton-Garc\u00eda J, Nowak P, et al.. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report. Am J Hematol. 2022, 97:E312-7. 10.1002\/ajh.26626","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.005","article-title":"Cancer, COVID-19, and antiviral immunity: the CAPTURE study","volume":"183","author":"Au L","year":"2020","unstructured":"Au L, Boos LA, Swerdlow A, Byrne F, Shepherd ST, Fendler A, Turajlic S. Cancer, COVID-19, and antiviral immunity: the CAPTURE study. Cell. 2020, 183:4-10. 10.1016\/j.cell.2020.09.005","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab700","article-title":"Incidence,  clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies","volume":"74","author":"Calder\u00f3n-Parra J","year":"2022","unstructured":"Calder\u00f3n-Parra J, M\u00fa\u00f1ez-Rubio E, Fern\u00e1ndez-Cruz A, et al.. Incidence,  clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies. Clin Infect Dis. 2022, 74:1786-94. 10.1093\/cid\/ciab700","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.03.002","article-title":"Successful use of casirivimab\/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19","volume":"28","author":"Miyazato Y","year":"2022","unstructured":"Miyazato Y, Yamamoto K, Nakaya Y, et al.. Successful use of casirivimab\/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19. J Infect Chemother. 2022, 28:991-4. 10.1016\/j.jiac.2022.03.002","journal-title":"J Infect Chemother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.05.003","article-title":"Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir","volume":"29","author":"Nakamura K","year":"2023","unstructured":"Nakamura K, Sugiyama M, Ishizuka H, et al.. Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir. J Infect Chemother. 2023, 29:820-4. 10.1016\/j.jiac.2023.05.003","journal-title":"J Infect Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14301","article-title":"Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: a narrative review","volume":"26","author":"Kinsella PM","year":"2024","unstructured":"Kinsella PM, Moso MA, Morrissey CO, et al.. Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: a narrative review. Transpl Infect Dis. 2024, 26:e14301. 10.1111\/tid.14301","journal-title":"Transpl Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243597","article-title":"Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients","volume":"15","author":"Kawasuji H","year":"2020","unstructured":"Kawasuji H, Takegoshi Y, Kaneda M, et al.. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLoS One. 2020, 15:e0243597. 10.1371\/journal.pone.0243597","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96143-8","article-title":"Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19","volume":"11","author":"Kawasuji H","year":"2021","unstructured":"Kawasuji H, Morinaga Y, Tani H, et al.. Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19. Sci Rep. 2021, 11:16535. 10.1038\/s41598-021-96143-8","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27282","article-title":"SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19","volume":"94","author":"Kawasuji H","year":"2022","unstructured":"Kawasuji H, Morinaga Y, Tani H, et al.. SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19. J Med Virol. 2022, 94:147-53. 10.1002\/jmv.27282","journal-title":"J Med Virol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1377014","article-title":"High interleukin-6 levels induced by COVID-19 pneumonia correlate with increased circulating follicular helper T cell frequency and strong neutralization antibody response in the acute phase of Omicron breakthrough infection","volume":"15","author":"Kawasuji H","year":"2024","unstructured":"Kawasuji H, Morinaga Y, Nagaoka K, et al.. High interleukin-6 levels induced by COVID-19 pneumonia correlate with increased circulating follicular helper T cell frequency and strong neutralization antibody response in the acute phase of Omicron breakthrough infection. Front Immunol. 2024, 15:1377014. 10.3389\/fimmu.2024.1377014","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2072455","article-title":"Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants","volume":"14","author":"Ozawa T","year":"2022","unstructured":"Ozawa T, Tani H, Anraku Y, et al.. Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. MAbs. 2022, 14:2072455. 10.1080\/19420862.2022.2072455","journal-title":"MAbs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05131-22","article-title":"Neutralizing antibody response of the wild-type\/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5","volume":"11","author":"Kawasuji H","year":"2023","unstructured":"Kawasuji H, Morinaga Y, Tani H, et al.. Neutralizing antibody response of the wild-type\/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5. Microbiol Spectr. 2023, 11:e0513122. 10.1128\/spectrum.05131-22","journal-title":"Microbiol Spectr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.05.077","article-title":"Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots","volume":"42","author":"Kawasuji H","year":"2024","unstructured":"Kawasuji H, Morinaga Y, Tani H, et al.. Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots. Vaccine. 2024, 42:126029. 10.1016\/j.vaccine.2024.05.077","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-021-01490-7","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein","volume":"18","author":"Tani H","year":"2021","unstructured":"Tani H, Kimura M, Tan L, et al.. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virol J. 2021, 18:16. 10.1186\/s12985-021-01490-7","journal-title":"Virol J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00560-21","article-title":"Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants","volume":"9","author":"Morinaga Y","year":"2021","unstructured":"Morinaga Y, Tani H, Terasaki Y, et al.. Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants. Microbiol Spectr. 2021, 9:e0056021. 10.1128\/Spectrum.00560-21","journal-title":"Microbiol Spectr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.10.007","article-title":"The unique presentation of SARS-CoV-2 infection in patients with B-cell depletion: definition of 'persistent inflammatory sero-negative COVID'","volume":"29","author":"Belkin A","year":"2023","unstructured":"Belkin A, Leibowitz A, Shargian L, Yahav D. The unique presentation of SARS-CoV-2 infection in patients with B-cell depletion: definition of 'persistent inflammatory sero-negative COVID'. Clin Microbiol Infect. 2023, 29:1-3. 10.1016\/j.cmi.2022.10.007","journal-title":"Clin Microbiol Infect"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958010-00009","article-title":"Rituximab","volume":"58","author":"Onrust SV","year":"1999","unstructured":"Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs. 1999, 58:79-88; discussion 89-90. 10.2165\/00003495-199958010-00009","journal-title":"Drugs"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad189","article-title":"Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir\/ritonavir: case series","volume":"10","author":"Breeden M","year":"2023","unstructured":"Breeden M, Aitken SL, Baang JH, et al.. Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir\/ritonavir: case series. Open Forum Infect Dis. 2023, 10:ofad189. 10.1093\/ofid\/ofad189","journal-title":"Open Forum Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/342145-successful-30-day-nirmatrelvirritonavir-treatment-of-a-patient-who-developed-multi-relapsed-covid-19-after-receiving-r-chop-against-follicular-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:17:28Z","timestamp":1739578648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/342145-successful-30-day-nirmatrelvirritonavir-treatment-of-a-patient-who-developed-multi-relapsed-covid-19-after-receiving-r-chop-against-follicular-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.79019","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}